120 related articles for article (PubMed ID: 11594577)
1. Pegylated doxorubicin for primary cutaneous T cell lymphoma: a report on ten patients with follow-up.
Wollina U; Graefe T; Kaatz M
Ann N Y Acad Sci; 2001 Sep; 941():214-6. PubMed ID: 11594577
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.
Pulini S; Rupoli S; Goteri G; Pimpinelli N; Alterini R; Bettacchi A; Mulattieri S; Picardi P; Tassetti A; Scortechini AR; Fioritoni G; Leoni P
Eur J Haematol; 2009 Mar; 82(3):184-93. PubMed ID: 19215609
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
Wollina U; Dummer R; Brockmeyer NH; Konrad H; Busch JO; Kaatz M; Knopf B; Koch HJ; Hauschild A
Cancer; 2003 Sep; 98(5):993-1001. PubMed ID: 12942567
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.
Pulini S; Rupoli S; Goteri G; Pimpinelli N; Alterini R; Tassetti A; Scortechini AR; Offidani M; Mulattieri S; Stronati A; Brandozzi G; Giacchetti A; Mozzicafreddo G; Ricotti G; Filosa G; Bettacchi A; Simonacci M; Novelli N; Leoni P
Haematologica; 2007 May; 92(5):686-9. PubMed ID: 17488695
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma.
Hau P; Fabel K; Baumgart U; Rümmele P; Grauer O; Bock A; Dietmaier C; Dietmaier W; Dietrich J; Dudel C; Hübner F; Jauch T; Drechsel E; Kleiter I; Wismeth C; Zellner A; Brawanski A; Steinbrecher A; Marienhagen J; Bogdahn U
Cancer; 2004 Mar; 100(6):1199-207. PubMed ID: 15022287
[TBL] [Abstract][Full Text] [Related]
6. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.
Quereux G; Marques S; Nguyen JM; Bedane C; D'incan M; Dereure O; Puzenat E; Claudy A; Martin L; Joly P; Delaunay M; Beylot-Barry M; Vabres P; Celerier P; Sasolas B; Grange F; Khammari A; Dreno B
Arch Dermatol; 2008 Jun; 144(6):727-33. PubMed ID: 18559761
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin in the treatment of cutaneous T-cell lymphoma.
Prince HM; Seymour JF; Ryan G; McCormack C
J Am Acad Dermatol; 2001 Jan; 44(1):149-50. PubMed ID: 11148501
[No Abstract] [Full Text] [Related]
8. Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.
Gardner JM; Evans KG; Goldstein S; Kim EJ; Vittorio CC; Rook AH
Arch Dermatol; 2009 Sep; 145(9):985-8. PubMed ID: 19770436
[No Abstract] [Full Text] [Related]
9. Pegylated liposomal doxorubicin in the treatment of mycosis fungoides.
Lybaek D; Iversen L
Acta Derm Venereol; 2006; 86(6):545-7. PubMed ID: 17106606
[No Abstract] [Full Text] [Related]
10. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
[No Abstract] [Full Text] [Related]
11. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
12. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
13. Childhood cutaneous natural killer/T lymphoma successfully treated with only one course of chemotherapy and incomplete tumor resection.
Miyazaki M; Lin YW; Okada M; Hamahata K; Kubota M
Haematologica; 2001 Aug; 86(8):883-4. PubMed ID: 11524256
[No Abstract] [Full Text] [Related]
14. Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants.
Quéreux G; Renaut JJ; Peuvrel L; Knol AC; Brocard A; Dréno B
Acta Derm Venereol; 2010 Nov; 90(6):616-20. PubMed ID: 21057746
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
Dumontet C; Thomas L; Bérard F; Gimonet JF; Coiffier B
Bull Cancer; 2006 Nov; 93(11):E115-8. PubMed ID: 17145574
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
Querfeld C; Rosen ST; Kuzel TM; Kirby KA; Roenigk HH; Prinz BM; Guitart J
Arch Dermatol; 2005 Mar; 141(3):305-11. PubMed ID: 15781671
[TBL] [Abstract][Full Text] [Related]
17. Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma.
Aldaoud A
Dermatol Clin; 2008 Jan; 26 Suppl 1():15-7. PubMed ID: 18405181
[No Abstract] [Full Text] [Related]
18. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin.
Wollina U; Graefe T; Karte K
J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):40-6. PubMed ID: 10607318
[TBL] [Abstract][Full Text] [Related]
19. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities.
Potouridou I; Korfitis C; Ioannidou D; Polydorou D; Zakopoulou N; Stratigos AJ; Katsambas AD
Br J Dermatol; 2008 Feb; 158(2):431-2. PubMed ID: 18067475
[No Abstract] [Full Text] [Related]
20. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up.
Wollina U; Graefe T; Kaatz M
J Cancer Res Clin Oncol; 2001 Feb; 127(2):128-34. PubMed ID: 11216914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
